[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$oncs](/topic/$oncs) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "$ONCS $CVAC $BNTX $ALNY $EBS $ADPT $ARCT $TBIO $VXRT $ATRA $VBIV $ALT $DVAX $IBIO $HTBX $TNXP $PDSB $TFX $GOVX $IGC $XNCR $FPRX $INCY $AGIO $GBT $HALO $ALKS $KPTI $CARA $ZGNX $TMO $EW $DXCM $IDXX $NVTA $HZNP $BMRN $VRTX $ABT $MDT $BSX $GME $AMC $BTC $jd $baba $anf $nvda $mstr" [X Link](https://x.com/edward_petez/status/1976719002023157923) [@edward_petez](/creator/x/edward_petez) 2025-10-10T18:38Z 1134 followers, XXX engagements "Barclays🏁 $ONC Overweight-$385 and said BeOne (ONC) is a commercial oncology company developing therapies across hematologic and solid tumors. $ONC's broad oncology pipeline positions it for durable growth. Barclay additionally said: We initiate coverage of BeOne (ONC) with an Overweight rating and $XXX PT ahead of two value-inflecting pivotal data readouts; 1) Data for BTK inhibitor in first line mantle cell lymphoma in 2H25; and 2) Data in first line gastroesophageal cancer for PD1 inhibitor + anti-HER2 combination in 4Q25" [X Link](https://x.com/Quantumup1/status/1968652175699071081) [@Quantumup1](/creator/x/Quantumup1) 2025-09-18T12:23Z 3845 followers, 1382 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$ONCS $CVAC $BNTX $ALNY $EBS $ADPT $ARCT $TBIO $VXRT $ATRA $VBIV $ALT $DVAX $IBIO $HTBX $TNXP $PDSB $TFX $GOVX $IGC $XNCR $FPRX $INCY $AGIO $GBT $HALO $ALKS $KPTI $CARA $ZGNX $TMO $EW $DXCM $IDXX $NVTA $HZNP $BMRN $VRTX $ABT $MDT $BSX $GME $AMC $BTC $jd $baba $anf $nvda $mstr"
X Link @edward_petez 2025-10-10T18:38Z 1134 followers, XXX engagements
"Barclays🏁 $ONC Overweight-$385 and said BeOne (ONC) is a commercial oncology company developing therapies across hematologic and solid tumors. $ONC's broad oncology pipeline positions it for durable growth. Barclay additionally said: We initiate coverage of BeOne (ONC) with an Overweight rating and $XXX PT ahead of two value-inflecting pivotal data readouts; 1) Data for BTK inhibitor in first line mantle cell lymphoma in 2H25; and 2) Data in first line gastroesophageal cancer for PD1 inhibitor + anti-HER2 combination in 4Q25"
X Link @Quantumup1 2025-09-18T12:23Z 3845 followers, 1382 engagements
/topic/$oncs/posts